07:33 AM EDT, 08/26/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Monday that the European Commission has approved Ordspono to treat adult patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy.

The company said that this marks the first regulatory approval of Ordspono worldwide for these patients, which is based on results from the phase 1 ELM-1 and phase 2 ELM-2 trials.

Price: 1,196.00, Change: -3.12, Percent Change: -0.26